anti nrf2  (Proteintech)

Journal: Materials Today Bio

Article Title: A novel biomimetic nanozyme orchestrates ulcerative colitis resolution by targeting KEAP1-NRF2-ARE pathway: Redox balance restoration, colonic barrier repair, immune homeostasis regulation

doi: 10.1016/j.mtbio.2025.102627

Figure Lengend Snippet: DhHP-6 NRF2-dependently alleviated oxidative stress at cellular levels. (A and H) Representative immunofluorescence of NRF2 nuclear translocation in LPS-treated Caco-2 cells and RAW264.7 cells, respectively. (B and I) Representative Western blot images of oxidant pathway (KEAP1, Nucleus NRF2, HO-1, and NQO1) in LPS-treated Caco-2 cells and RAW264.7 cells. (C and J) The level of ROS by DCFH-DA in LPS-treated Caco-2 cells and RAW264.7 cells. (D-G and K-N) Redox indicators levels (MDA, CAT, GSH, and SOD) in LPS-treated Caco-2 cells and RAW264.7 cells. Data (expressed as mean ± standard deviation) were derived from the specified number of independent experiments (n = 3). Significance levels were denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, compared to the control group.

Article Snippet: Following blocking with 5 % non-fat milk in TBST for 1 h at 25 °C, the membranes were probed with primary antibodies at 4 °C overnight: anti-CD86 (1:1000; HUABIO ET1606-50), anti-CD206 (1:1000; HUABIO ET1702-04), anti-KEAP1(1:800; Proteintech 10503-2-AP) anti-NRF2 (1:1000; Proteintech D1Z9C), anti-HO-1 (1:1000; Proteintech R380753), anti-NQO1 (1:1000; ZEN-BIOSCIENCE R381695), anti-BCL-2 (1:1000; Proteintech 12789-1-AP), anti-BAX (1:1000; Proteintech 50599-2-Ig), anti-Cleaved Caspase-3 (1:800; Proteintech 25128-1-AP), anti-phospho-IκBα (1:1000; Proteintech 82349-1-RR), anti-IκBα (1:1000; Abcam Ab32518), anti-p-P65 (1:1000; Proteintech 3033T), anti-P65 (1:1000; Proteintech 10745-1-AP), and anti-β-actin (1:3000; Proteintech 66009-1-Ig).

Techniques: Immunofluorescence, Translocation Assay, Western Blot, Standard Deviation, Derivative Assay, Control

Journal: Materials Today Bio

Article Title: A novel biomimetic nanozyme orchestrates ulcerative colitis resolution by targeting KEAP1-NRF2-ARE pathway: Redox balance restoration, colonic barrier repair, immune homeostasis regulation

doi: 10.1016/j.mtbio.2025.102627

Figure Lengend Snippet: DhHP-6 activated NRF2 in luciferase reporter assays and interferes with the interaction between KEAP1 and NRF2. (A–B) Luciferase assays for NRF2 activation in Caco-2 and RAW264.7 cells, respectively. (C–D) Alphafold3 prediction analysis of DhHP-6 interacting with the Kelch domain of KEAP1 protein in Caco-2 and RAW264.7 cells, respectively. (E) Sequence logo at key residues generated via Logomaker based on multiple sequence alignment of KEAP1. Data (expressed as mean ± standard deviation) were derived from the specified number of independent experiments (n = 3). Significance levels were denoted as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, compared to the control group.

Article Snippet: Following blocking with 5 % non-fat milk in TBST for 1 h at 25 °C, the membranes were probed with primary antibodies at 4 °C overnight: anti-CD86 (1:1000; HUABIO ET1606-50), anti-CD206 (1:1000; HUABIO ET1702-04), anti-KEAP1(1:800; Proteintech 10503-2-AP) anti-NRF2 (1:1000; Proteintech D1Z9C), anti-HO-1 (1:1000; Proteintech R380753), anti-NQO1 (1:1000; ZEN-BIOSCIENCE R381695), anti-BCL-2 (1:1000; Proteintech 12789-1-AP), anti-BAX (1:1000; Proteintech 50599-2-Ig), anti-Cleaved Caspase-3 (1:800; Proteintech 25128-1-AP), anti-phospho-IκBα (1:1000; Proteintech 82349-1-RR), anti-IκBα (1:1000; Abcam Ab32518), anti-p-P65 (1:1000; Proteintech 3033T), anti-P65 (1:1000; Proteintech 10745-1-AP), and anti-β-actin (1:3000; Proteintech 66009-1-Ig).

Techniques: Luciferase, Activation Assay, Sequencing, Generated, Standard Deviation, Derivative Assay, Control

Journal: Materials Today Bio

Article Title: A novel biomimetic nanozyme orchestrates ulcerative colitis resolution by targeting KEAP1-NRF2-ARE pathway: Redox balance restoration, colonic barrier repair, immune homeostasis regulation

doi: 10.1016/j.mtbio.2025.102627

Figure Lengend Snippet: Schematic diagram illustrating the potential mechanism of DhHP-6 in UC management. DhHP-6 activates the KEAP1-NRF2-ARE pathway, thereby contributing to redox balance restoration, colonic barrier repair, and immune homeostasis regulation. The schematic images were created with the assistance of the Figdraw platform.

Article Snippet: Following blocking with 5 % non-fat milk in TBST for 1 h at 25 °C, the membranes were probed with primary antibodies at 4 °C overnight: anti-CD86 (1:1000; HUABIO ET1606-50), anti-CD206 (1:1000; HUABIO ET1702-04), anti-KEAP1(1:800; Proteintech 10503-2-AP) anti-NRF2 (1:1000; Proteintech D1Z9C), anti-HO-1 (1:1000; Proteintech R380753), anti-NQO1 (1:1000; ZEN-BIOSCIENCE R381695), anti-BCL-2 (1:1000; Proteintech 12789-1-AP), anti-BAX (1:1000; Proteintech 50599-2-Ig), anti-Cleaved Caspase-3 (1:800; Proteintech 25128-1-AP), anti-phospho-IκBα (1:1000; Proteintech 82349-1-RR), anti-IκBα (1:1000; Abcam Ab32518), anti-p-P65 (1:1000; Proteintech 3033T), anti-P65 (1:1000; Proteintech 10745-1-AP), and anti-β-actin (1:3000; Proteintech 66009-1-Ig).

Techniques: